Comparative Pharmacology
Head-to-head clinical analysis: CEFACLOR versus CEFOTETAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFACLOR versus CEFOTETAN.
CEFACLOR vs CEFOTETAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
250-500 mg orally every 8 hours
1 to 2 g intravenously or intramuscularly every 12 hours. For severe infections, up to 2 g every 12 hours for 5-10 days.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour; prolonged to 2-3 hours in renal impairment
Clinical Note
moderateCefotetan + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefotetan."
Clinical Note
moderateCefaclor + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefaclor."
Clinical Note
moderateCefotetan + Ethanol
"The risk or severity of adverse effects can be increased when Cefotetan is combined with Ethanol."
Clinical Note
moderateCefotetan + Picosulfuric acid
3-4.5 hours (6-8 hours in renal impairment).
Renal: 60-85% unchanged in urine within 8 hours; biliary/fecal: minor, ~5%
Renal (80-90% unchanged), biliary (small amount, up to 20% in bile), fecal (<5%).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefotetan."